• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Solid Biosciences (SLDB)

Common Shares
Sell: $6.60|Buy: $7.48|Change: 0.18 (2.50%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Address

141 Portland Street
Fifth Floor
Cambridge
MA
USA
02139

Telephone

+1 617 3374680

Website

https://www.solidbio.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Solid Biosciences Inc Fourth Quarter Earnings Results for 20262027-03-19T00:00:00
Solid Biosciences Inc Annual Report for 20262027-03-19T00:00:00
Solid Biosciences Inc Third Quarter Earnings Results for 20262026-11-03T00:00:00
Solid Biosciences Inc Second Quarter Earnings Results for 20262026-08-12T00:00:00
Solid Biosciences Inc Annual General Meeting for 20262026-06-12T08:00:00
Solid Biosciences Inc First Quarter Earnings Results for 20262026-05-15T00:00:00

Previous key dates

NameKey Date
Solid Biosciences Inc Fourth Quarter Earnings Results for 20252026-03-19T00:00:00
Solid Biosciences Inc Annual Report for 20252026-03-19T00:00:00
Guggenheim Emerging Outlook: Biotech Summit 20262026-02-12T10:30:00
44th Annual J.P. Morgan Healthcare Conference2026-01-13T08:15:00
Piper Sandler 37th Annual Healthcare Conference2025-12-02T11:30:00
Jefferies Global Healthcare Conference2025-11-18T06:00:00
Solid Biosciences Inc Third Quarter Earnings Results for 20252025-11-03T00:00:00
Baird Global Healthcare Conference 20252025-09-09T15:10:00
H.C. Wainwright 27th Annual Global Investment Conference 20252025-09-08T09:00:00
Cantor Global Healthcare Conference 20252025-09-04T15:20:00
Citi Biopharma Back to School Conference 20252025-09-02T13:45:00
Solid Biosciences Inc Second Quarter Earnings Results for 20252025-08-12T00:00:00
Solid Biosciences Inc Annual General Meeting for 20252025-06-12T08:00:00
Solid Biosciences Inc First Quarter Earnings Results for 20252025-05-15T00:00:00
The Citizens Life Sciences Conference2025-05-07T00:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.